These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37833590)

  • 1. Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.
    Roeske MJ; McHugo M; Rogers B; Armstrong K; Avery S; Donahue M; Heckers S
    Neuropsychopharmacology; 2024 Mar; 49(4):681-689. PubMed ID: 37833590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
    Tsai JJ; Yen DJ; Hsih MS; Chen SS; Hiersemenzel R; Edrich P; Lai CW
    Epilepsia; 2006 Jan; 47(1):72-81. PubMed ID: 16417534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
    Ben-Menachem E; Falter U
    Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
    Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
    Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam in patients with central neuropathic post-stroke pain--a randomized, double-blind, placebo-controlled trial.
    Jungehulsing GJ; Israel H; Safar N; Taskin B; Nolte CH; Brunecker P; Wernecke KD; Villringer A
    Eur J Neurol; 2013 Feb; 20(2):331-7. PubMed ID: 22925226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of levetiracetam as adjunctive treatment for refractory canine epilepsy: a randomized, placebo-controlled, crossover trial.
    Muñana KR; Thomas WB; Inzana KD; Nettifee-Osborne JA; McLucas KJ; Olby NJ; Mariani CJ; Early PJ
    J Vet Intern Med; 2012; 26(2):341-8. PubMed ID: 22295869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
    Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
    Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid onset of action of levetiracetam in refractory epilepsy patients.
    French J; Arrigo C
    Epilepsia; 2005 Feb; 46(2):324-6. PubMed ID: 15679515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study.
    Solaro C; de Sire A; Messmer Uccelli M; Mueller M; Bergamaschi R; Gasperini C; Restivo DA; Stabile MR; Patti F
    Eur J Neurol; 2020 Nov; 27(11):2209-2216. PubMed ID: 32558044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.
    Hardy BT; Patterson EE; Cloyd JM; Hardy RM; Leppik IE
    J Vet Intern Med; 2012; 26(2):334-40. PubMed ID: 22295898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function--a TMS study.
    Reis J; Wentrup A; Hamer HM; Mueller HH; Knake S; Tergau F; Oertel WH; Rosenow F
    Epilepsy Res; 2004 Nov; 62(1):41-51. PubMed ID: 15519131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.
    Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z;
    Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials.
    Gidal BE; Sheth RD; Magnus L; Herbeuval AF
    Epilepsy Res; 2003 Oct; 56(2-3):121-6. PubMed ID: 14642996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study).
    Borggraefe I; Bonfert M; Bast T; Neubauer BA; Schotten KJ; Maßmann K; Noachtar S; Tuxhorn I; May TW; Heinen F;
    Eur J Paediatr Neurol; 2013 Sep; 17(5):507-14. PubMed ID: 23642492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults.
    Schoenberg MR; Rum RS; Osborn KE; Werz MA
    Epilepsia; 2017 Sep; 58(9):1566-1574. PubMed ID: 28731266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levetiracetam on focal nocturnal epileptiform activity during sleep--a placebo-controlled double-blind cross-over study.
    Larsson PG; Bakke KA; Bjørnæs H; Heminghyt E; Rytter E; Brager-Larsen L; Eriksson AS
    Epilepsy Behav; 2012 May; 24(1):44-8. PubMed ID: 22494796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
    Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
    Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.